Summary Analysis of tissue sections from transurethrally resected bladder tumours using anti-CD3 antibody showed the presence of T lymphocytes in intra-epithelial layers in eight of 12 cases investigated. In a larger group of patients, Tumour Infiltrating Lymphocyte (TIL) growth was established from six of 19 cases using Interleukin-2 (IL-2) and conditioned medium (CM) and resulted in the expansion of TILs up to 100-fold. TILs from these individuals were phenotyped with W6/32 (anti-HLA-A,B,C), HB55 
Recently there has been speculation from results in vitro studies that interleukin-2 induced T lymphocyte mediated tumour rejection response may be the mechanism by which intravesical BCG produces durable long term disease free survival in more than 50% of patients with recurrent superficial bladder cancer (Anon, 1991; Ratliff et al., 1991) . As a consequence, there has been increased interest in study of T lymphocyte activity in bladder tumours since it has long been known that the extent of lymphocyte infiltration in tumours is of prognostic significance (Dayan et al., 1964; Pomerance, 1972; Tsujihashi et al., 1989) .
Studies of melanoma patients have demonstrated that IL-2 can be used to expand TILs from tumour biopsy (Topalian et al., 1987) and in nearly half the cases these TILs showed HLA class I antigen restricted T cell cytotoxicity against the autologous tumour (Itoh et al., 1988) . These cells labelled with a neomycin resistance gene have been demonstrated in the circulation for up to 200 days, and at sites where the tumour underwent rejection, up to 70 days after injection (Rosenberg et al., 1990) . This has provided the most convincing evidence to date that T lymphocytes can induce tumour rejection particularly when taken together with the recent report that the T cell receptor of melanoma TILs show restricted V alpha gene rearrangements (Nitta et al., 1990) demonstrating their oligoclonality.
For other adult.solid tumours study of TILs has failed to demonstrate HLA class I-restricted cytotoxity (CTL). One possible factor explaining this has come from the recent studies in bladder cancer. These have demonstrated that more than 50% of bladder tumours have variable degrees of polymorphic or monomorphic HLA class I antigen loss (Nouri et al., 1990) as an immune escape mechanism in association with P h C G expression (Oliver et al., 1989) . This paper set out to study generation of TILs from bladder cancer biopsies and investigated the influence of HLA class I expression on the ability to generate TILs.
Materials and methods
Operative specimens from the Urology Department of the Royal London Hospital were used immediately after operation. The tissues were divided into two portions the smaller of which was snap frozen and kept in liquid nitrogen for tissue sectioning. The second portion was washed, minced and the resulting cell suspension and tissue fragments were used for developing tumour cell lines. Where there were sufficient cells available, attempts were made to develop TILs according to the following protocol.
The cell preparation was incubated overnight in RPMI containing 10% foetal calf serum in the presence or absence of recombinant IL-2 (100 u ml', Biogen). After the incubation the non-adherent cells were removed, spun down and resuspended at 0.5 x 106 ml-l in medium containing IL-2 and cultured in a separate flask. In the cases where single cell suspension from the 1st passage contained a large amount of cell debris, density gradient separation was carried out to remove cell debris. The cells from resulting interface cell ie, mainly lymphocytes were removed and cultured in medium with IL-2. TILs from successful cases were fed every 2 or 3 days by adjusting the cell number to 0.5 x 106ml-'. After 2 weeks of culture, CM (5% v/v, see below) was added to the IL-2 medium in order to increase the rate of cell proliferation.
The adherent cells were fed until confluence (1 to 2 x 106 25 cm2 flask) and were expanded by trypsinising the cells and sub-culturing into new flasks at a lower density (0.5 x 10625 cm-2 flask).
Conditioned medium
This was prepared by activating normal peripheral blood mononuclear cells (prepared from density gradient separated blood) at 2x 106ml-' with PHA at 2 fgml-' for 2h at 37C. The cells were washed three times and resuspended in medium at 2 x 106 ml-' and culturing continued for a further 36 h. After the incubation cell-free supernatant was removed, aliquoted and frozen until use.
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and K562 (myelocytic cell) or our own established bladder cancer cell line (WIL) were labelled with 5"Cr (250 pCi/target) for 1 h at 37C followed by extensive washes. These cells i.e. target cells (T) were mixed (three replicates/treatment) with TILs i.e. effector cells (E) to give E/T ratios of 3.2/1, 6.5/1, 12.5/1 and 25/1 in round-bottomed microtitre plates. The cell mixtures were incubated for different lengths of times, after which cell-free supernatants were removed and counted using a gamma counter. The specific killing activity for each treatment was calculated using standard formulae.
Flourescent staining
Cell suspension was prepared in round-bottomed tube to give 0.5 x 106/tube. After centrifugation, supernatant was discarded and cells were resuspended in 50 ftl of appropriate antibody and incubated for 45 min at room temperature. Cells were washed in PBS and FITC-conjugated rabbit anti-mouse i.e. 2nd antibody (1/50 dilution, Dakopatts) was added and incubation continued for a further 45 min. After three washes, the cell pellets were used for FACS analysis.
Tissue staining Frozen sections were cut using a cryostat at a thickness of 7 Lm, placed on microscope slides, air dried and kept at -40°C until use. A peroxidase-antiperoxidase staining method was employed as previously reported by Nouri et al. (1990) .
Monoclonal antibodies
The monoclonal antibodies (Mabs) used as primary reagents in the form of tissue culture supernatants, together with their specificities are listed: W6/32 detects all ,2m-associated HLA-A,B,C antigens (Nouri et al., 1990) , BBM.1 detects ,2m (Nouri et al., 1990) , HC1O detects non-P2 associated HLA-A,B,C antigens (Stam et al., 1986) , L243 detects HLA-DR (Lampson et al., 1980) , anti-CD3, -CD4 and -CD8 (Ortho-pharmaceutical) detect total T, T helper and T suppressor/cytotoxic lymphocytes subsets respectively.
Cell proliferation Proliferation of cells was measured by incorporation of tritiated thymidine (3H-Tdr, 0.1 ,Ci/well, Amersham) into cellular DNA. TILs were dispensed into round-bottomed microtitre plates at 0.5 x 106 well in three replicates and incubated in the presence or the absence of stimulus for 48 h, the last 4 h of which was in the presence of 3H-Tdr. In an attempt to maximise cell yield, TIL proliferation was studied with IL-2 alone and IL-2 plus CM results of which are shown in Figure 1 . The addition of CM (5%) to IL-2-activated cells increased the thymidine incorporation (0.5 x 106 cell/well) from 5,200c.p.m. to 19,800c.p.m. (3.8-fold period of 10 days are presented in Figure 2 . Figure 3 . As can be seen, at all the E/T ratios, the longer the incubation period the greater the degree of tumour killing. Furthermore, as the ratios of E/T increased the degree of cell killing also increased. Thus at 4 h the specific killing at 3.2/1, 6.5/1, 12.5/1 and 25/1 E/T ratios were 10.2 ± 1.2, 19.6 ± 3.2, 25.6 ± 6.3 and 34.5 ± 4.2% respec- tively 4 h incubation time was chosen and used for subsequent experiments. The ability of cultured TILs (expanded in vitro for more than 2 weeks) to kill different well established allogeneic human cells lines was investigated. The results of TIL from WIL are presented in Figure 4 . As expected, there was a direct correlation between E/T ratios and tumour target killing. Daudi cells were found to be the most sensitive target followed by Molt 4, whereas U937 and K562 showed equally low sensitivity. Thus, the percent specific killing for Daudi cells at 25/1, 12.5/1, 6.5/1 and 3.2/1 were 62.8 ± 5.2, 59.5 ± 3.2, 44.7 ± 6.2 and 35.2 ± 3.7% respectively. The degree of specific tumour target killing against Daudi cells by TILs from FS, JF, FB, AW, LR were 35.5 ± 4.2, 26.3 ± 3.2, 45.4 + 5.9, 33.5 ± 4.8 and 55.5 ± 5.3% respectively. In addition TILs from WIL (same individual from which permanent cell line has been established) were found to be capable of killing autologous tumour cells at 25/1 ratios by 15.8 ± 1.6% compared with 7.3 ± 1.9% killing of another epithelial cell line (SKV14, UV-transformed foreskin epithelial line), indicating the low level of specific killing of these cells against autologous tumour cells.
60
TIL phenotypes The presence of T cell markers (CD3, CD4 and CD8) and HLA class I and II antigens were studied in TILs from six individuals after being in culture for more than 30 days (Table I) . Given the long standing observation that prognosis of bladder cancer patients correlates with the degree of lymphocyte infiltration (Pomerance et at., 1972; Tsujihashi, 1989) and recent understanding of the effects of IL-2 on lymphocyte activation, it is hardly surprising that IL-2 treatment of bladder tumour biopsies should lead to the clonal expansion of activated T lymphocytes. This raises the question why tumour progression occurs despite the presence of lymphocytes at the tumour site.
Our studies showed that TILs were only generated from those tumours with normal HLA class I antigens as measured by a presence of staining with W6/32 antibody. This may imply that T cells infiltrate and possibly proliferate .at tumour sites where there is normal expression of class I antigen acting as an associative molecules for presentation of putative neo-antigens. However, 54% of those tumours with apparently normal class I expression measured by W6/32 failed to develop TILs. The lack of availability of monoclonal antibodies against all the polymorphic class I antigens which are critical for assessing the extent of MHC antigen abnormality might be one explanation for the observed discrepancy. Other factors including the size or the degree of lymphocytes infiltration into tumour biospies may also be important and these are currently under investigation.
The low levels of specific killing of TILs from WIL against the autologous tumour cells line (15.8 ± 1.6%) is in agreement with the above observation since analysis of MHC class I antigens on these cells demonstrated that although HLA A locus antigens A2 and A3 were normally expressed the cells lacked totally the HLA-B locus antigens B7 and B44 (Nouri et al., 1991) .
It has been disappointing that all of the bladder TILs have demonstrated non-specific NK/LAK-like activity in contrast to TILs from melanomas, 30-40% of whlch have demonstrated class I restricted T-cell mediated CTL. Studies in animal and in vitro have demonstrated that the levels of class I antigen expression correlate with the level of specific cytotoxic T cell killing (Hui et al., 1984) and inversely correlates with NK/LAK killing (Storkus et al., 1987) . To date there have been no reports on such detailed study of polymorphic HLA class I expression, on human tumours. It would be interesting to establish whether the frequency of loss of polymorphic class I antigens could correlate with the lack of MHC restricted CTL killing activity in most human TILs and whether correction of the defect by transfection of lost antigen led to the development of specific CTL.
In renal cell (Belldegrum et al., 1988) and bladder cancer (Pape et al., 1979) , there are a minority of tumours demonstrating evidence of possible T cell mediated immune reactions. If we are ever to harness the full potential of immune rejection of cancer, there is a need to develop techniques to identify the minority of cases with normal HLA expression using formalin fixed tissue as they may well be the group who will show maximum benefit from immunological treatments like IL-2 and BCG.
There has been increasing anecdotal evidence for involvement of papilloma virus in bladder tumour development (Querci Della Rovere et al., 1988; Bryant et al., 1991) . Preliminary information from our own work has demonstrated more frequent reactivity of anti-HPV16 E7 antibody with superficial than invasive tumour (Oliver, 1989) . As loss of HLA class I is also more frequent in invasive tumours (Nouri et al., 1990) , it is possible that HPV antigen in association with appropriate HLA could be explored as possible vaccine for cancer patients (Anon, 1989) .
